The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Management of trypanosomiasis and leishmaniasis
Open accessAbstract
BACKGROUND: The current treatments for human African trypanosomiasis (HAT), Chagas disease and leishmaniasis (collectively referred to as the kinetoplastid diseases) are far from ideal but, for some, there has been significant recent progress. For HAT the only advances in treatment over the past two decades have been the introduction of an eflornithine/nifurtimox co-administration and a shorter regime of the old standard melarsoprol. SOURCES OF DATA: PubMed. AREAS OF AGREEMENT: There is a need for new safe, oral drugs for cost-effective treatment of patients and use in control programmes for all the trypanosomatid diseases. AREAS OF CONTROVERSY: Cutaneous leishmaniasis is not on the agenda and treatments are lagging behind. GROWING POINTS: There are three compounds in development for the treatment of the CNS stage of HAT: fexinidazole, currently due to entry into phase II clinical studies, a benzoxaborole (SCYX-7158) in phase I trials and a diamidine derivative (CPD-0802), in advanced pre-clinical development. For Chagas disease, two anti-fungal triazoles are now in clinical trial. In addition, clinical studies with benznidazole, a drug previously recommended only for acute stage treatment, are close to completion to determine the effectiveness in the treatment of early chronic and indeterminate Chagas disease. For visceral leishmaniasis new formulations, therapeutic switching, in particular AmBisome, and the potential for combinations of established drugs have significantly improved the opportunities for the treatment in the Indian subcontinent, but not in East Africa. AREAS TIMELY FOR DEVELOPING RESEARCH: Improved diagnostic tools are needed to support treatment, for test of cure in clinical trials and for monitoring/surveillance of populations in control programmes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bulletin of the World Health Organization
C., N. H. (1955) · The British Journal of Sociology · doi:10.2307/587237 · Cited by 3,601
(2024) · Pharmacological Reviews · doi:10.1124/pr · Cited by 2,664
Rassi, A., Rassi, A., & Marin-Neto, J. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60061-x · Cited by 2,119
Drug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663
Self-citationVisceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., Alvar, J., & Boelaert, M. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1748 · Cited by 1,490
Reithinger, R., Dujardin, J.-C., Louzir, H., Pirmez, C., Alexander, B., & Brooker, S. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70209-8 · Cited by 1,334
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Cañavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., López-Vélez, R., & Moreno, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00061-07 · Cited by 937
Brun, R., Blum, J., Chappuis, F., & Burri, C. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60829-1 · Cited by 926
Comparative Genomics of Trypanosomatid Parasitic Protozoa
El-Sayed, N. M., Myler, P. J., Blandin, G., Berriman, M., Crabtree, J., Aggarwal, G., Caler, E., Renauld, H., Worthey, E. A., Hertz-Fowler, C., et al. (2005) · Science · doi:10.1126/science.1112181 · Cited by 819
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Barrett, M. P., Burchmore, R. J., Stich, A., Lazzari, J. O., Frasch, A. C., Cazzulo, J. J., & Krishna, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14694-6 · Cited by 656
Self-citationKinetoplastids: related protozoan pathogens, different diseases
Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gürtler, R. E., McKerrow, J., Reed, S., & Tarleton, R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33945 · Cited by 604
Self-citationPriotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Ghorashian, S., Arnold, U., Ghabri, S., Baudin, E., Buard, V., Kazadi-Kyanza, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61117-x · Cited by 533
Injectable Paromomycin for Visceral Leishmaniasis in India
Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066536 · Cited by 471
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 434
Leishmaniasis chemotherapy—challenges and opportunities
Croft, S. L., & Olliaro, P. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03630.x · Cited by 424
Self-citationOptions for Field Diagnosis of Human African Trypanosomiasis
Chappuis, F., Loutan, L., Simarro, P., Lejon, V., & Büscher, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.133-146.2005 · Cited by 362
Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507530 · Cited by 345
Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease
Barrett, M. P., Boykin, D. W., Brun, R., & Tidwell, R. R. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707354 · Cited by 338
Self-citationSundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 337
Torreele, E., Bourdin Trunz, B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., Bray, M. A., & Pécoul, B. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000923 · Cited by 325
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
Jacobs, R. T., Nare, B., Wring, S. A., Orr, M. D., Chen, D., Sligar, J. M., Jenks, M. X., Noe, R. A., Bowling, T. S., Mercer, L. T., et al. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001151 · Cited by 305
High-throughput decoding of antitrypanosomal drug efficacy and resistance
Alsford, S., Eckert, S. E., Baker, N., Glover, L., Sánchez‐Flores, A., Leung, K. F., Turner, D. J., Field, M. C., Berriman, M., & Horn, D. (2012) · Nature · doi:10.1038/nature10771 · Cited by 303
Recent research on the biological activity of suramin.
Voogd, T. E., Vansterkenburg, E. L., Wilting, J., & Janssen, L. H. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00445-4 · Cited by 285
Eflornithine for the treatment of human African trypanosomiasis
Burri, C., & Brun, R. (2003) · Parasitology Research · doi:10.1007/s00436-002-0766-5 · Cited by 227
Interventions for American cutaneous and mucocutaneous leishmaniasis
González, U., Pinart, M., Rengifo-Pardo, M., Macaya, A., Alvar, J., & Tweed, J. A. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004834.pub2 · Cited by 204
Interventions for Old World cutaneous leishmaniasis
Heras-Mosteiro, J., Monge-Maillo, B., Pinart, M., Lopez Pereira, P., Reveiz, L., Garcia-Carrasco, E., Campuzano Cuadrado, P., Royuela, A., Mendez Roman, I., & López-Vélez, R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005067.pub5 · Cited by 196
A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes
Vincent, I. M., Creek, D., Watson, D. G., Kamleh, M. A., Woods, D. J., Wong, P. E., Burchmore, R. J. S., & Barrett, M. P. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001204 · Cited by 184
Self-citationDrug discovery and development for neglected diseases: the DNDi model
Ioset, J.-R., & Chatelain (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s16381 · Cited by 182
Two approaches to discovering and developing new drugs for Chagas disease
McKerrow, J., Doyle, P., Engel, J., Podust, L., Robertson, S., Ferreira, R., Saxton, T., Arkin, M., Kerr, I., Brinen, L., et al. (2009) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762009000900034 · Cited by 177
Berman, J. D., Badaró, R. J. D. S., Thakur, C. P., Wasunna, K. M., Behbehani, K., Davidson, R. N., Kuzoe, F. A. S., Pang, L. W., Weerasuriya, K., & Bryceson, A. D. M. (1998) · Europe PMC (PubMed Central) · Cited by 171
Burri, C., Nkunku, S., Merolle, A., Smith, T., Blum, J., & Brun, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02141-3 · Cited by 170
Target assessment for antiparasitic drug discovery
Frearson, J. A., Wyatt, P. G., Gilbert, I. H., & Fairlamb, A. H. (2007) · Trends in Parasitology · doi:10.1016/j.pt.2007.08.019 · Cited by 144
Development of Novel Drugs for Human African Trypanosomiasis
Brun, R., Don, R., Jacobs, R. T., Wang, M. Z., & Barrett, M. P. (2011) · Future Microbiology · doi:10.2217/fmb.11.44 · Cited by 138
Self-citationDiamidines for human African trypanosomiasis.
Paine, M. F., Wang, M. Z., Generaux, C., et al. (2010) · PubMed · Cited by 117
The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill
Vanhollebeke, B., & Pays, E. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07156.x · Cited by 105
Designing and Reporting Clinical Trials on Treatments for Cutaneous Leishmaniasis
González, U., Pinart, M., Revéiz, L., Rengifo‐Pardo, M., Tweed, J., Macaya, A., & Alvar, J. (2010) · Clinical Infectious Diseases · doi:10.1086/655134 · Cited by 76
Rodgers, J., Jones, A. L., Gibaud, S., et al. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001308 · Cited by 63
Cited by
Epidemiology of visceral leishmaniasis
Ready, P. (2014) · Clinical Epidemiology · doi:10.2147/clep.s44267 · Cited by 471
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Resveratrol: A miraculous natural compound for diseases treatment
Koushki, M., Amiri‐Dashatan, N., Ahmadi, N., Abbaszadeh, H., & Rezaei‐Tavirani, M. (2018) · Food Science & Nutrition · doi:10.1002/fsn3.855 · Cited by 316
The trypanosome alternative oxidase: a potential drug target?
MENZIES, S. K., TULLOCH, L. B., FLORENCE, G. J., & SMITH, T. K. (2018) · Parasitology · doi:10.1017/s0031182016002109 · Cited by 44
Metadata
- Authors
- Barrett, M. P., & Croft, S. L.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-07
- Volume
- 104
- Issue
- 1
- Pages
- 175-196
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2161670666
- Cited by
- 304
- References
- 38
- FWCI
- 14.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.